Conditions: Colorectal Cancer; Angiogenesis Intervention: Procedure: COLORECTAL CANCER SURGERY Sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau Recruiting (Source: ClinicalTrials.gov)MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.
Wed Oct 30, 2019 17:00
Conditions: Breast Cancer; Necrosis Intervention: Diagnostic Test: ICG microangiography Sponsor: University of Wisconsin, Madison Recruiting (Source: ClinicalTrials.gov)
Wed Oct 30, 2019 17:00
Condition: Microsatellite-stable Colorectal Cancer Interventions: Drug: Standard of Care - mFOLFOX6; Drug: E1 - mFOLFOX and durvalumab; Drug: E2 - mFOLFOX6, durvalumab and oleclumab; Drug: E3 - mFOLFOX6, durvalumab and monalizumab Sponsor: MedImmune LLC Not yet recruiting (Source: ClinicalTrials.gov)
Wed Oct 30, 2019 17:00
Conditions: Head and Neck Cancer; Pain; Dysfunction Intervention: Other: Manual therapy Sponsor: Universidad de Granada Recruiting (Source: ClinicalTrials.gov)
Wed Oct 30, 2019 17:00
Condition: Colorectal Cancer Intervention: Dietary Supplement: Phenylalanine intake Sponsor: University of Alberta Not yet recruiting (Source: ClinicalTrials.gov)
Wed Oct 30, 2019 17:00
Condition: Colorectal Cancer Interventions: Diagnostic Test: mt-sDNA 2.0 screening test; Diagnostic Test: FIT test; Procedure: Colonoscopy Sponsor: Exact Sciences Corporation Not yet recruiting (Source: ClinicalTrials.gov)MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.
Wed Oct 30, 2019 17:00
Condition: Metastatic or Non-driver Gene Mutation Non-small Cell Lung Cancer Intervention: Drug: Sintilimab Combined With Docetaxel Monotherapy Sponsor: Yongchang Zhang Recruiting (Source: ClinicalTrials.gov)
Wed Oct 30, 2019 17:00
Conditions: Insomnia, Secondary; Breast Cancer Female; Chemotherapy Interventions: Procedure: Electroacupuncture (EA) and Auricular Acupressure (AA); Procedure: Sham Electroacupuncture (SE) and Sham Auricular Acupressure (SA) Sponsor: The University of Hong Kong Not yet recruiting (Source: ClinicalTrials.gov)
Wed Oct 30, 2019 17:00
Condition: Prostate Cancer Interventions: Behavioral: Soccer; Behavioral: mHealth Sponsor: Emory University Recruiting (Source: ClinicalTrials.gov)
Wed Oct 30, 2019 17:00
Conditions: Biochemically Recurrent Prostate Carcinoma; Prostate Adenocarcinoma; PSA Failure; PSA Progression Interventions: Combination Product: Carbon C 11 Choline; Procedure: Computed Tomography; Other: Gallium Ga 68-labeled PSMA-11; Procedure: Positron Emission Tomography Sponsors: Mayo Clinic; National Cancer Institute (NCI) Recruiting (Source: ClinicalTrials.gov)
Wed Oct 30, 2019 17:00
Condition: Metastatic Breast Cancer Interventions: Drug: Vinorelbine; Drug: Gemcitabine; Drug: Carboplatin Sponsor: Shandong Cancer Hospital and Institute Not yet recruiting (Source: ClinicalTrials.gov)MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.
Wed Oct 30, 2019 17:00
Conditions: Glioblastoma, IDH-Mutant; Recurrent Glioblastoma Interventions: Biological: Ipilimumab; Biological: Nivolumab Sponsor: National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Wed Oct 30, 2019 17:00
Condition: Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion Intervention: Drug: larotrectinib(Vitrakvi, BAY2757556) Sponsor: Bayer Not yet recruiting (Source: ClinicalTrials.gov)
Tue Oct 29, 2019 17:00
Condition: Gastrointestinal Stromal Tumor Interventions: Other: DNA extraction of tumer tissue samples and high-throughput sequencing of small panels; Other: DNA extraction of tumer tissue samples and blood sample and high-throughput sequencing of small panels Sponsors: The First Affiliated Hospital with Nanjing Medical University; Fudan University Recruiting (Source: ClinicalTrials.gov)
Tue Oct 29, 2019 17:00
Condition: Metastatic Breast Cancer Intervention: Drug: Metformin Sponsor: Hager salah el din Recruiting (Source: ClinicalTrials.gov)MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.
Tue Oct 29, 2019 17:00
Condition: Musculoskeletal Malignancy Interventions: Behavioral: Personalized acceptance-based mindfulness exercise; Behavioral: Brief educational pamphlet Sponsor: Massachusetts General Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Tue Oct 29, 2019 17:00
Condition: Hepatocellular Carcinoma Interventions: Drug: Sorafenib; Procedure: Transarterial chemoembolization Sponsor: Sun Yat-sen University Recruiting (Source: ClinicalTrials.gov)
Tue Oct 29, 2019 17:00
Condition: Pancreatic Adenocarcinoma Intervention: Sponsors: Van Andel Research Institute; Spectrum Health Hospitals; Mercy Health Not yet recruiting (Source: ClinicalTrials.gov)
Tue Oct 29, 2019 17:00
Conditions: Chronic Disease; Diabetes; Vascular Diseases; Chronic Lung Disease; Cancer; Psychiatric Disorder Intervention: Device: Telemedicine: tablet and possibly tools to perform measurements Sponsors: University of Oslo; Oslo Economics; Norwegian Centre for Rural Medicine; Norsk Gallup Institutt AS Recruiting (Source: ClinicalTrials.gov)
Tue Oct 29, 2019 17:00
Condition: Breast Cancer Intervention: Drug: Enzalutamide Sponsor: SOLTI Breast Cancer Research Group Not yet recruiting (Source: ClinicalTrials.gov)
Tue Oct 29, 2019 17:00
Condition: Breast Cancer Intervention: Other: interview Sponsor: Centre Georges Francois Leclerc Recruiting (Source: ClinicalTrials.gov)MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.
Tue Oct 29, 2019 17:00
Conditions: Stage IV Non-small Cell Lung Cancer; Stage IV Melanoma; Triple Negative Breast Cancer; Renal Cell Carcinoma Stage IV Intervention: Combination Product: ImmunicomAIAC Sponsor: Prof. Gal Markel Not yet recruiting (Source: ClinicalTrials.gov)
Tue Oct 29, 2019 17:00
Condition: Hematological Malignancies Intervention: Sponsors: Tampere University Hospital; Tampere University; University of Eastern Finland Not yet recruiting (Source: ClinicalTrials.gov)
Tue Oct 29, 2019 17:00
Condition: Oncologic Disorders Intervention: Other: Care pathway Sponsors: Ilyse Kenis; Kom Op Tegen Kanker; KU Leuven; University Ghent Not yet recruiting (Source: ClinicalTrials.gov)
Tue Oct 29, 2019 17:00
Conditions: Breast Cancer; Breast Neoplasms; Triple Negative Breast Cancer; HER2-positive Breast Cancer Intervention: Drug: Parsaclisib Sponsors: UNC Lineberger Comprehensive Cancer Center; Incyte Corporation Not yet recruiting (Source: ClinicalTrials.gov)
Tue Oct 29, 2019 17:00
Condition: Breast Cancer Intervention: Drug: Onapristone Sponsor: SOLTI Breast Cancer Research Group Not yet recruiting (Source: ClinicalTrials.gov)
Tue Oct 29, 2019 17:00
Conditions: HIV Infection; Human Papillomavirus Infection; Human Papillomavirus-Related Carcinoma Interventions: Other: Cytology Specimen Collection Procedure; Procedure: High Resolution Anoscopy with Biopsy; Other: Laboratory Biomarker Analysis; Procedure: Medical Examination; Procedure: Physical Examination; Other: Questionnaire Administration Sponsors: AIDS Malignancy Consortium; National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)MedWorm Message:...
Tue Oct 29, 2019 17:00
Condition: HIV Infection Interventions: Other: Cytology Specimen Collection Procedure; Other: Laboratory Biomarker Analysis; Procedure: Medical Examination; Procedure: Physical Examination; Procedure: Proctoscopy with Biopsy; Other: Questionnaire Administration Sponsors: AIDS Malignancy Consortium; National Cancer Institute (NCI); Tata Memorial Hospital; Udaan Trust; University of Arkansas Not yet recruiting (Source: ClinicalTrials.gov)
Tue Oct 29, 2019 17:00
Condition: Colorectal Cancer Liver Metastases Interventions: Diagnostic Test: [18-F]- FDG - PET; Procedure: Thermal ablation (TA); Diagnostic Test: PET/CT Scan Sponsor: Memorial Sloan Kettering Cancer Center Recruiting (Source: ClinicalTrials.gov)
Tue Oct 29, 2019 17:00
One in eight American women will develop breast cancer in their lifetime. But the aggressive treatment many relay on to save lives can sometimes cause hearty problems years after treatment. Dr. Tara Narula explains. (Source: Health News: CBSNews.com)
Thu Oct 31, 2019 10:49
Contrast-enhanced digital mammography (CEDM) and molecular breast imaging (MBI)...Read more on AuntMinnie.comRelated Reading: Image processing shows potential to reduce MBI dose MBI useful in particular breast screening scenarios CEDM a useful alternative for breast cancer screening Tissue enhancement affects breast MRI interpretation Preop breast MRI forecasts positive tumor margins (Source: AuntMinnie.com Headlines)
Thu Oct 31, 2019 08:00
Massachusetts General Hospital researchers found that innoccuous HPV that lives on the skin activates T-cells which in turn fight DNA mutations that can lead to skin cancer, suggesting a viral vaccine. (Source: the Mail online | Health)
Thu Oct 31, 2019 02:17
Eight years after her double mastectomy, Giuliana Rancic is now a mom – and she and her husband are speaking about a program that helps mothers going through cancer (Source: Health News: CBSNews.com)
Wed Oct 30, 2019 23:05
The drug AMG 510 was tested on four lung cancer patients. Two patients saw their tumours reduce, according to the pharmaceutical giant Amgen Research, California. (Source: the Mail online | Health)
Wed Oct 30, 2019 21:49
WEDNESDAY, Oct. 30, 2019 -- Only one in four U.S. adults report incorporating cancer prevention into their daily lives, according to the results of the American Society of Clinical Oncology 2019 National Cancer Opinion Survey. The Harris Poll... (Source: Drugs.com - Pharma News)
Wed Oct 30, 2019 20:00
ConclusionsThis study showed that unintended rectal preservation increases oncologic risk after neoadjuvant chemoradiotherapy for rectal cancer regardless of short-term follow-up. Therefore, these findings could be shared with rectal cancer patients who choose to ignore medical advice after chemoradiotherapy to preserve their rectum. (Source: World Journal of Surgery)
Thu Oct 31, 2019 13:15
ConclusionsIn a large number of patients with LPLNSM on initial imaging, metastatic LPLN are present after nCRT and surgical treatment. Even in LPLN that are considered responsive on restaging, significant rates of pathologically confirmed metastases are reported. (Source: World Journal of Surgery)
Thu Oct 31, 2019 13:15
ConclusionsOur findings are hypothesis generating and highlight the potential safety of major cancer surgery in the HIV population. However, care providers need be cognizant of the potential increased risk of post-operative complications following pulmonary lobectomy and the potential for increased length of stay. These findings are an initial insight into quality of care and outcomes metrics on HIV patients undergoing major cancer operations. (Source: World Journal of Surgery)
Thu Oct 31, 2019 13:15
ConclusionsThe annual incidence of mesothelioma has not declined this century and remains stable. Reporting of histologic and clinical staging has improved. National trends suggest that survival is slowly increasing despite an aging cohort. Multimodal therapy and treatment at academic centers are modifiable risk factors associated with improved survival. (Source: World Journal of Surgery)MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social...
Thu Oct 31, 2019 13:15
ConclusionsIn this study, MSI, EMAST, andRAS/RAF alterations did not influence the oncological outcomes. Overall, LVI and MC were two significant prognostic factors for DFS and DR. Thus, the histopathology, rather than the genes, plays a major role in the prognosis of patients with stage II CRC. (Source: World Journal of Surgery)
Thu Oct 31, 2019 13:15
ConclusionsThis meta-analysis suggests that LCME in right colon cancer surgery is superior to OCME in terms of overall morbidity, blood loss, hospital stay, and local and distant recurrence with a moderate grade of recommendation due to the retrospective nature of the included studies. (Source: World Journal of Surgery)
Thu Oct 31, 2019 13:15
Authors: Esposito A, Balduzzi A, De Pastena M, Fontana M, Casetti L, Ramera M, Bassi C, Salvia R Abstract Introduction: Minimally invasive surgery (MIS) for pancreatic cancer has become very popular in modern pancreatic surgery. Evidence of the benefits of an MI approach are increasing thanks to prospective studies and randomized controlled studies.Areas covered: Agreement is lacking regarding the oncological feasibility of MIS for pancreatic cancer. Therefore, we performed a systematic...
Thu Oct 31, 2019 13:10
Authors: Sasako M Abstract Introduction: Today, there is a global consensus that adjuvant treatment is mandatory for stage II and III gastric cancer. What remains controversial, however, is what constitutes the best adjuvant therapy. A comprehensive review including published papers, doi documents and abstracts from the ASCO annual meeting was undertaken to develop this updated review.Areas covered: Adjuvant treatments for stage II or more advanced and potentially curable gastric and gastroesophageal...
Thu Oct 31, 2019 13:10
Authors: Milano MT, Mihai A, Kang J, Singh DP, Verma V, Qiu H, Chen Y, Kong FS Abstract Introduction: Lung dosimetric constraints with stereotactic body/ablative radiotherapy (SBRT/SABR) for multiple lung lesions are not well-characterized in published literature. Classically, lung is considered a 'parallel' organ, for which injury to functional subunits could result in partially compromised function of that organ/tissue. Therefore, with SBRT/SABR for >1 thoracic target (especially involving...
Thu Oct 31, 2019 13:10
Interleukin (IL)-22 activates STAT (signal transducer and activator of transcription) 3 and anti-apoptotic and pro-proliferative pathways; but beyond this, the molecular mechanisms by which IL-22 promotes carcinogenesis are poorly understood.Characterizing the molecular signature of IL-22 in human DLD-1 colon carcinoma cells, we observed increased expression of 26 genes, including NNMT (nicotinamide N-methyltransferase, ≤10-fold) and CEA (carcinoembryonic antigen, ≤7-fold), both known to promote...
Thu Oct 31, 2019 13:03
Obesity is increasing in incidence in New Zealand. Maintaining loco-regional control following breast cancer surgery is important as this can improve overall survival. While obesity has been associated with poorer survival in breast cancer, the correlation with locoregional control is less well evaluated and was the subject of this evaluation. (Source: International Journal of Radiation Oncology * Biology * Physics)
Thu Oct 31, 2019 12:37
Among breast-cancer patients presenting with cN1 disease, nodal pathologic complete response (ypN0) after neoadjuvant chemotherapy (NACT) was associated with decreased likelihood of post-mastectomy and post-lumpectomy nodal radiation (NRT). There was no survival benefit associated with nodal (vs no) radiation in ypN0 patients post-mastectomy, but benefit approached significance among ypN1 patients. NRT was associated with improved survival for ypN0 and ypN1 patients post-lumpectomy but this benefit...
Thu Oct 31, 2019 12:37
NCTXXXXXX was a phase II prospective trial in which non-small lung cancer patients were randomized to local consolidative therapy (LCT) versus maintenance therapy or observation (MT/O). (Source: International Journal of Radiation Oncology * Biology * Physics)
Thu Oct 31, 2019 12:37
To evaluate whether automated knowledge-based planning (KBP) is (a) non-inferior to human-driven planning across multiple disease sites and (b) systematically impacts dosimetric plan quality and variability. (Source: International Journal of Radiation Oncology * Biology * Physics)
Thu Oct 31, 2019 12:37
Two illustrative applications are presented of Bayesian clinical trial designs that make adaptive subgroup-specific decisions based on elicited utilities of patient outcomes to quantify risk-benefit trade-offs. The first design is for a randomized trial to evaluate effects of nutritional prehabilitation on post-operative morbidity in esophageal cancer patients undergoing surgery. The second design is for a dose-finding trial of natural killer cells to treat advanced hematologic malignancies, with...
Thu Oct 31, 2019 12:36
ConclusionSIS is a hopeful DCE-MRI angiogenic biomarker to assess preoperative treatment response after SCR with delayed surgery. Furthermore, an important prognostic role was obtained by VARPROFp mean value pre-treatment and by a decision tree composed by diffusion parameters derived by DWI and DKI to assess pathological complete response. (Source: Abdominal Imaging)
Thu Oct 31, 2019 12:35
ConclusionDiffusivity derived from the baseline staging MRI, but not diffusion kurtosis or volumetric data, is associated with TRG and therefore shows promise as a potential imaging biomarker to predict the response to neoadjuvant chemotherapy in LARC.Clinical relevance statementDiffusivity shows promise as a potential imaging biomarker to predict AJCC TRG following neoadjuvant CRT, which has implications for risk stratification. Patients with TRG 0/1 have 5-year disease-free survival (DFS) of 90...
Thu Oct 31, 2019 12:35
AbstractEvaluation of primary rectal cancer specimens places the pathologist in a unique position relative to peers, as it is one of the few specimens where the report influences not just patient outcomes but also the quality of the surgical technique itself. With ever-increasing data indicating that the completeness of the mesorectal excision and adequate resection margins are critical for reduced local recurrence rates and improved clinical outcome, the pathologist is faced with the challenge of...
Thu Oct 31, 2019 12:35
(Source: Abdominal Imaging)
Thu Oct 31, 2019 12:35
ConclusionsAdding DWI to HRT2w significantly improved specificity for the detection of perirectal infiltration at primary staging by experienced radiologists and also by inexperienced ones, although to a lesser extent. In the post-neoadjuvant treatment subgroup, only minimal changes were observed. (Source: Abdominal Imaging)MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via...
Thu Oct 31, 2019 12:35
AbstractCombined PET/MRI is a proposed imaging modality for rectal cancer, leveraging the advantages of MRI and 18F-fluorodeoxyglucose PET. Rectal cancer PET/MRI protocols typically include dedicated pelvis bed positions utilizing small field-of-view T2-weighted imaging. For staging of the primary tumor, PET/MRI can help delineate the extent of tumor better as well as the extent of tumor beyond the muscularis propria. PET uptake may help characterize small lymph nodes, and the use of hepatobiliary...
Thu Oct 31, 2019 12:35
ConclusionUltrahighb value (b2000) may improve rectal cancer conspicuity and introbserver agreement maintaining comparable diagnostic accuracy to standard b1000. (Source: Abdominal Imaging)
Thu Oct 31, 2019 12:35
AbstractThere is a wide array of pathological lesions seen in the anorectal region with CT colonography (CTC), much of which is unique to this location. Many relatively common findings in the anorectal region are typically benign, but can be misinterpreted as malignant. There are also technique-related pitfalls that can impede accurate diagnosis of anorectal findings at CTC. Understanding common and uncommon lesions in the anorectal region as well as recognizing technical pitfalls will optimize interpretation...
Thu Oct 31, 2019 12:35
Authors: Motta I, Mancarella M, Marcon A, Vicenzi M, Cappellini MD Abstract Introduction: β-Thalassemia syndromes are among the most common monogenic disorders worldwide. Clinically, on the basis of the severity of the phenotype, β-thalassemias are classified into two groups: transfusion-dependent thalassemia (TDT) and non-transfusion-dependent thalassemia (NTDT). In the last few decades, considerable advances in understanding the pathophysiology of β-thalassemia have significantly improved...
Thu Oct 31, 2019 12:28
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου